智通财经APP讯，康希诺生物(06185)发布2024年度业绩快报，营业总收入8.46亿元(人民币，单位下同)，同比增长137.01%;归属于母公司所有者的净亏损3.79亿元，同比收窄74.45%;基本每股亏损1.53元。
报告期内，营业总收入同比增加137.01%，变动主要系：MCV4作为中国市场上唯一的四价流脑结合疫苗，集团通过对其市场的精准布局推动持续放量，产品渗透率不断提升，实现销量快速增长;同时，集团经营受全球公共卫生事件的影响已经基本消除。因此，集团营业收入较去年同期大幅增长。
智通财经APP讯，康希诺生物(06185)发布2024年度业绩快报，营业总收入8.46亿元(人民币，单位下同)，同比增长137.01%;归属于母公司所有者的净亏损3.79亿元，同比收窄74.45%;基本每股亏损1.53元。
报告期内，营业总收入同比增加137.01%，变动主要系：MCV4作为中国市场上唯一的四价流脑结合疫苗，集团通过对其市场的精准布局推动持续放量，产品渗透率不断提升，实现销量快速增长;同时，集团经营受全球公共卫生事件的影响已经基本消除。因此，集团营业收入较去年同期大幅增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.